Guardant Health Begins Patient Enrollment In National Cancer Institute's Vanguard Study To Evaluate Emerging Multi-Cancer Detection Technology

Benzinga · 07/15 15:02
  • Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participants
  • Shield MCD reviewed by FDA as part of NCI's investigational device exemption (IDE)

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)'s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant's Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials.

Guardant's Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The Vanguard study was initiated following review and approval by the U.S. Food and Drug Administration (FDA) as part of the NCI's submission for an investigational device exemption (IDE).